ITH Stock Overview
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Nektar Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.46 |
| 52 Week High | US$1.46 |
| 52 Week Low | US$0.39 |
| Beta | 0.91 |
| 1 Month Change | 79.70% |
| 3 Month Change | 201.59% |
| 1 Year Change | 57.41% |
| 3 Year Change | -90.94% |
| 5 Year Change | -94.62% |
| Change since IPO | -86.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| ITH | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 14.9% | 0.4% | -1.2% |
| 1Y | 57.4% | -29.0% | 1.2% |
Return vs Industry: ITH exceeded the German Pharmaceuticals industry which returned -29.7% over the past year.
Return vs Market: ITH exceeded the German Market which returned 2.1% over the past year.
Price Volatility
| ITH volatility | |
|---|---|
| ITH Average Weekly Movement | 17.9% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: ITH's share price has been volatile over the past 3 months.
Volatility Over Time: ITH's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 137 | Howard Robin | www.nektar.com |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system’s natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Nektar Therapeutics Fundamentals Summary
| ITH fundamental statistics | |
|---|---|
| Market cap | €272.68m |
| Earnings (TTM) | -€259.47m |
| Revenue (TTM) | €84.71m |
3.4x
P/S Ratio-1.1x
P/E RatioIs ITH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ITH income statement (TTM) | |
|---|---|
| Revenue | US$90.12m |
| Cost of Revenue | US$33.77m |
| Gross Profit | US$56.35m |
| Other Expenses | US$332.41m |
| Earnings | -US$276.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.50 |
| Gross Margin | 62.53% |
| Net Profit Margin | -306.31% |
| Debt/Equity Ratio | 86.0% |
How did ITH perform over the long term?
See historical performance and comparison